Cargando…

Elite and posttreatment controllers, two facets of HIV control

The quest for HIV-1 cure could take advantage of the study of rare individuals that control viral replication spontaneously (elite controllers) or after an initial course of antiretroviral therapy (posttreatment controllers, PTCs). In this review, we will compare back-to-back the immunological and v...

Descripción completa

Detalles Bibliográficos
Autores principales: Mastrangelo, Andrea, Banga, Riddhima, Perreau, Matthieu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10004771/
https://www.ncbi.nlm.nih.gov/pubmed/35938466
http://dx.doi.org/10.1097/COH.0000000000000751
_version_ 1784904917624815616
author Mastrangelo, Andrea
Banga, Riddhima
Perreau, Matthieu
author_facet Mastrangelo, Andrea
Banga, Riddhima
Perreau, Matthieu
author_sort Mastrangelo, Andrea
collection PubMed
description The quest for HIV-1 cure could take advantage of the study of rare individuals that control viral replication spontaneously (elite controllers) or after an initial course of antiretroviral therapy (posttreatment controllers, PTCs). In this review, we will compare back-to-back the immunological and virological features underlying viral suppression in elite controllers and PTCs, and explore their possible contributions to the HIV-1 cure research. RECENT FINDINGS: HIV-1 control in elite controllers shows hallmarks of an effective antiviral response, favored by genetic background and possibly associated to residual immune activation. The immune pressure in elite controllers might select against actively transcribing intact proviruses, allowing the persistence of a small and poorly inducible reservoir. Evidence on PTCs is less abundant but preliminary data suggest that antiviral immune responses may be less pronounced. Therefore, these patients may rely on distinct mechanisms, not completely elucidated to date, suppressing HIV-1 transcription and replication. SUMMARY: PTCs and elite controllers may control HIV replication using distinct pathways, the elucidation of which may contribute to design future interventional strategies aiming to achieve a functional cure.
format Online
Article
Text
id pubmed-10004771
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-100047712023-03-11 Elite and posttreatment controllers, two facets of HIV control Mastrangelo, Andrea Banga, Riddhima Perreau, Matthieu Curr Opin HIV AIDS CONTROLLERS AND NATURAL CURES: Edited by Matthieu Perreau The quest for HIV-1 cure could take advantage of the study of rare individuals that control viral replication spontaneously (elite controllers) or after an initial course of antiretroviral therapy (posttreatment controllers, PTCs). In this review, we will compare back-to-back the immunological and virological features underlying viral suppression in elite controllers and PTCs, and explore their possible contributions to the HIV-1 cure research. RECENT FINDINGS: HIV-1 control in elite controllers shows hallmarks of an effective antiviral response, favored by genetic background and possibly associated to residual immune activation. The immune pressure in elite controllers might select against actively transcribing intact proviruses, allowing the persistence of a small and poorly inducible reservoir. Evidence on PTCs is less abundant but preliminary data suggest that antiviral immune responses may be less pronounced. Therefore, these patients may rely on distinct mechanisms, not completely elucidated to date, suppressing HIV-1 transcription and replication. SUMMARY: PTCs and elite controllers may control HIV replication using distinct pathways, the elucidation of which may contribute to design future interventional strategies aiming to achieve a functional cure. Lippincott Williams & Wilkins 2022-09 2022-07-25 /pmc/articles/PMC10004771/ /pubmed/35938466 http://dx.doi.org/10.1097/COH.0000000000000751 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/)
spellingShingle CONTROLLERS AND NATURAL CURES: Edited by Matthieu Perreau
Mastrangelo, Andrea
Banga, Riddhima
Perreau, Matthieu
Elite and posttreatment controllers, two facets of HIV control
title Elite and posttreatment controllers, two facets of HIV control
title_full Elite and posttreatment controllers, two facets of HIV control
title_fullStr Elite and posttreatment controllers, two facets of HIV control
title_full_unstemmed Elite and posttreatment controllers, two facets of HIV control
title_short Elite and posttreatment controllers, two facets of HIV control
title_sort elite and posttreatment controllers, two facets of hiv control
topic CONTROLLERS AND NATURAL CURES: Edited by Matthieu Perreau
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10004771/
https://www.ncbi.nlm.nih.gov/pubmed/35938466
http://dx.doi.org/10.1097/COH.0000000000000751
work_keys_str_mv AT mastrangeloandrea eliteandposttreatmentcontrollerstwofacetsofhivcontrol
AT bangariddhima eliteandposttreatmentcontrollerstwofacetsofhivcontrol
AT perreaumatthieu eliteandposttreatmentcontrollerstwofacetsofhivcontrol